myricx pharma limited
myricx pharma limited Company Information
Company Number
12082645
Website
-Registered Address
125 wood street, london, EC2V 7AW
Industry
Research and experimental development on biotechnology
Telephone
-
Next Accounts Due
April 2025
Group Structure
View All
Shareholders
sofinnova capital ix 41%
hostplus pty ltd (hpst) 19.2%
View Allmyricx pharma limited Estimated Valuation
Pomanda estimates the enterprise value of MYRICX PHARMA LIMITED at £1.4m based on a Turnover of £1m and 1.39x industry multiple (adjusted for size and gross margin).
myricx pharma limited Estimated Valuation
Pomanda estimates the enterprise value of MYRICX PHARMA LIMITED at £0 based on an EBITDA of £-2.1m and a 5.69x industry multiple (adjusted for size and gross margin).
myricx pharma limited Estimated Valuation
Pomanda estimates the enterprise value of MYRICX PHARMA LIMITED at £0 based on Net Assets of £-3.7m and 2.24x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Myricx Pharma Limited Overview
Myricx Pharma Limited is a live company located in london, EC2V 7AW with a Companies House number of 12082645. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in July 2019, it's largest shareholder is sofinnova capital ix with a 41% stake. Myricx Pharma Limited is a young, small sized company, Pomanda has estimated its turnover at £1m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Myricx Pharma Limited Health Check
Pomanda's financial health check has awarded Myricx Pharma Limited a 2 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 5 areas for improvement. Company Health Check FAQs
2 Strong
3 Regular
5 Weak
Size
annual sales of £1m, make it smaller than the average company (£3.6m)
- Myricx Pharma Limited
£3.6m - Industry AVG
Growth
3 year (CAGR) sales growth of 32%, show it is growing at a faster rate (11.9%)
- Myricx Pharma Limited
11.9% - Industry AVG
Production
with a gross margin of 54.4%, this company has a comparable cost of product (54.4%)
- Myricx Pharma Limited
54.4% - Industry AVG
Profitability
an operating margin of -210.3% make it less profitable than the average company (-1.1%)
- Myricx Pharma Limited
-1.1% - Industry AVG
Employees
with 8 employees, this is below the industry average (42)
8 - Myricx Pharma Limited
42 - Industry AVG
Pay Structure
on an average salary of £74.9k, the company has an equivalent pay structure (£74.9k)
- Myricx Pharma Limited
£74.9k - Industry AVG
Efficiency
resulting in sales per employee of £125.3k, this is equally as efficient (£125.8k)
- Myricx Pharma Limited
£125.8k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Myricx Pharma Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 296 days, this is slower than average (62 days)
- Myricx Pharma Limited
62 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Myricx Pharma Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 9 weeks, this is less cash available to meet short term requirements (34 weeks)
9 weeks - Myricx Pharma Limited
34 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 324.7%, this is a higher level of debt than the average (52.7%)
324.7% - Myricx Pharma Limited
52.7% - Industry AVG
MYRICX PHARMA LIMITED financials
Myricx Pharma Limited's latest turnover from July 2023 is estimated at £1 million and the company has net assets of -£3.7 million. According to their latest financial statements, Myricx Pharma Limited has 8 employees and maintains cash reserves of £985.1 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jul 2023 | Jul 2022 | Jul 2021 | Jul 2020 | |
|---|---|---|---|---|
| Turnover | ||||
| Other Income Or Grants | ||||
| Cost Of Sales | ||||
| Gross Profit | ||||
| Admin Expenses | ||||
| Operating Profit | ||||
| Interest Payable | ||||
| Interest Receivable | ||||
| Pre-Tax Profit | ||||
| Tax | ||||
| Profit After Tax | ||||
| Dividends Paid | ||||
| Retained Profit | ||||
| Employee Costs | ||||
| Number Of Employees | 8 | 6 | 5 | 4 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jul 2023 | Jul 2022 | Jul 2021 | Jul 2020 | |
|---|---|---|---|---|
| Tangible Assets | 47,482 | 64,852 | 82,026 | 3,292 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 47,482 | 64,852 | 82,026 | 3,292 |
| Stock & work in progress | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 |
| Misc Debtors | 607,579 | 667,735 | 605,790 | 323,318 |
| Cash | 985,106 | 1,526,888 | 884,571 | 1,570,643 |
| misc current assets | 0 | 0 | 0 | 0 |
| total current assets | 1,592,685 | 2,194,623 | 1,490,361 | 1,893,961 |
| total assets | 1,640,167 | 2,259,475 | 1,572,387 | 1,897,253 |
| Bank overdraft | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 |
| Trade Creditors | 370,912 | 155,199 | 91,274 | 126,997 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 |
| other short term finances | 4,924,475 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 |
| other current liabilities | 18,444 | 120,989 | 45,380 | 16,146 |
| total current liabilities | 5,313,831 | 276,188 | 136,654 | 143,143 |
| loans | 0 | 3,162,247 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 |
| provisions | 11,170 | 16,125 | 20,420 | 609 |
| total long term liabilities | 11,170 | 3,178,372 | 20,420 | 609 |
| total liabilities | 5,325,001 | 3,454,560 | 157,074 | 143,752 |
| net assets | -3,684,834 | -1,195,085 | 1,415,313 | 1,753,501 |
| total shareholders funds | -3,684,834 | -1,195,085 | 1,415,313 | 1,753,501 |
| Jul 2023 | Jul 2022 | Jul 2021 | Jul 2020 | |
|---|---|---|---|---|
| Operating Activities | ||||
| Operating Profit | ||||
| Depreciation | 20,244 | 19,169 | 11,777 | 452 |
| Amortisation | 0 | 0 | 0 | 0 |
| Tax | ||||
| Stock | 0 | 0 | 0 | 0 |
| Debtors | -60,156 | 61,945 | 282,472 | 323,318 |
| Creditors | 215,713 | 63,925 | -35,723 | 126,997 |
| Accruals and Deferred Income | -102,545 | 75,609 | 29,234 | 16,146 |
| Deferred Taxes & Provisions | -4,955 | -4,295 | 19,811 | 609 |
| Cash flow from operations | ||||
| Investing Activities | ||||
| capital expenditure | ||||
| Change in Investments | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||
| Financing Activities | ||||
| Bank loans | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 4,924,475 | 0 | 0 | 0 |
| Long term loans | -3,162,247 | 3,162,247 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 |
| share issue | ||||
| interest | ||||
| cash flow from financing | ||||
| cash and cash equivalents | ||||
| cash | -541,782 | 642,317 | -686,072 | 1,570,643 |
| overdraft | 0 | 0 | 0 | 0 |
| change in cash | -541,782 | 642,317 | -686,072 | 1,570,643 |
myricx pharma limited Credit Report and Business Information
Myricx Pharma Limited Competitor Analysis
Perform a competitor analysis for myricx pharma limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in EC2V area or any other competitors across 12 key performance metrics.
myricx pharma limited Ownership
MYRICX PHARMA LIMITED group structure
Myricx Pharma Limited has no subsidiary companies.
Ultimate parent company
MYRICX PHARMA LIMITED
12082645
myricx pharma limited directors
Myricx Pharma Limited currently has 6 directors. The longest serving directors include Maina Bhaman (Oct 2019) and Dr Robin Carr (Oct 2022).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Maina Bhaman | 52 years | Oct 2019 | - | Director | |
| Dr Robin Carr | United Kingdom | 64 years | Oct 2022 | - | Director |
| Mr Jonathan Tobin | United Kingdom | 41 years | Apr 2023 | - | Director |
| Mr Christopher Martin | United Kingdom | 66 years | Nov 2023 | - | Director |
| Mr Michael Bauer | Denmark | 61 years | Jun 2024 | - | Director |
| Dr Lucille Conroy | United Kingdom | 34 years | Jun 2024 | - | Director |
P&L
July 2023turnover
1m
+51%
operating profit
-2.1m
0%
gross margin
54.4%
+0.72%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
July 2023net assets
-3.7m
+2.08%
total assets
1.6m
-0.27%
cash
985.1k
-0.35%
net assets
Total assets minus all liabilities
myricx pharma limited company details
company number
12082645
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
July 2019
age
5
incorporated
UK
accounts
Total Exemption Full
ultimate parent company
previous names
N/A
last accounts submitted
July 2023
address
125 wood street, london, EC2V 7AW
accountant
-
auditor
-
myricx pharma limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to myricx pharma limited.
myricx pharma limited Companies House Filings - See Documents
| date | description | view/download |
|---|
